Pharmaceuticals

Redhill Biopharma

Redhill Biopharma released FY2025 Annual Earnings on April 27 Post-Market (EST), actual revenue USD 286 K, actual EPS USD -0.1357

Redhill Biopharma released FY2025 Q4 earnings on April 27, 2026 (EST) with actual revenue of USD 0 and EPS of USD 0

Redhill Biopharma released FY2025 9 Months Earnings on April 27 (EST), actual revenue USD 4.079 M, actual EPS USD -2.2922

Redhill Biopharma released FY2025 Q3 earnings on April 27, 2026 (EST) with actual revenue USD 0 and actual EPS USD 0

RedHill Biopharma Announces Positive Preclinical Results for Opaganib in Combination with Venetoclax for Chronic Lymphocytic Leukemia

Cumberland Pharmaceuticals Makes Strategic Investment in RedHill Biopharma

RedHill Biopharma Signs License Agreement for Talicia with Middle East Market

Redhill Biopharma released FY2025 Q2 earnings on September 5 (EST), actual revenue USD 2.04 M, actual EPS USD -1.1461

Redhill Biopharma released FY2025 Q1 earnings on September 5 (EST), actual revenue USD 2.04 M, actual EPS USD -1.1461

Redhill Biopharma released FY2025 Semi-Annual Earnings on September 5, 2025 (EST) with actual revenue of USD 4.079 M and EPS of USD -2.2922

RedHill Biopharma Launches Phase II Clinical Trial for New Prostate Cancer Treatment

RedHill Biopharma signs stock purchase agreement with Alumni Capital

RedHill Supports H. pylori CME Program

RHB-107 Molecular Structure Receives Patent Protection

RedHill Biopharma Receives NASDAQ Non-Compliance Notice

RedHill's Opaganib Shows Progress in Obesity and Diabetes Management

Redhill Biopharma released FY2024 Q4 earnings on April 10 (EST), actual revenue USD 0, actual EPS USD 0

Redhill Biopharma released FY2024 Q3 earnings on April 10 EST with actual revenue of USD 0 and EPS of USD 0

Redhill Biopharma released FY2024 Annual Earnings on April 10 EST, actual revenue USD 0 (forecast USD 20.8 M), actual EPS USD -6.7095 (forecast USD -40)

Redhill Biopharma released FY2024 9 Months Earnings on April 10 (EST), actual revenue USD 2.572 M, actual EPS USD -2.6257

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

RDHL

RedHill Biopharma reported its 2025 results, highlighting the creation of Talicia Holdings and a co-commercialization deal with Cumberland Pharmaceuticals. The company expanded Talicia's reach and advanced its R&D focus on Crohn's disease and oncology. Financially, RedHill improved from a $4.7 million capital deficiency in 2024 to $4.3 million positive equity by year-end 2025. Despite ongoing losses, the stock is rated Neutral by TipRanks' AI Analyst due to weak financial performance and mixed technical indicators. RedHill focuses on gastrointestinal and inflammatory diseases and oncology, targeting both U.S. and international markets.

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

Cumberland Pharma

Humana

RedHill Biopharma Reshapes Talicia Franchise and Strengthens Balance Sheet in 2025 Results

CPIX

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | CPIX Stock News

StockTitan

VG Health

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares US Pharma

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | CPIX Stock News

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | CPIX Stock News

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | CPIX Stock News

TNON

The H. pylori infections market is projected to grow at a CAGR of 9.5% from 2026 to 2036, driven by advancements in treatment strategies and emerging therapies. The market size was USD 270 million in 2025, with the US holding 85% of the market share. Key players include TenNor Therapeutics and Cinclus Pharma, developing new drugs like Rifasutenizol and Linaprazan glurate. Factors such as rising prevalence, improved diagnostics, and the launch of new therapies are expected to drive growth in this sector.

SPDR S&P Health Equip

Tenon Medical

iShares US Medical Devices

CINCOR PHARMA INC

iShares Global Healthcare

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight | CPIX Stock News

KALA

INVZ

NINE

SELX

Market Overview of US Stocks in the Last Hour The US stock market has shown a significant sector rotation in the last hour, with the pharmaceutical and technology sectors performing particularly well. Capital flows are concentrated in small-cap stocks and thematic stocks, with high short-term enthusiasm. The overall market pace is fast, with large fluctuations, and investor sentiment is active. The stock with the largest movement in the last hour, Kala Pharmaceuticals, rose by 20.13%, becoming the most eye-catching stock during this period. A large influx of funds has driven the stock price to rise rapidly, with high short-term sentiment. Strong stocks: 1. Innoviz Tech: up 17.07%, the strong performance of the technology sector has driven the stock's rise, with active short-term capital involvement. 2. Nine Energy: up 11.22%, the recovery of the energy sector has significantly benefited this stock, with notable capital inflows. 3. Cue BioPharma: up 9.51%, the overall strength of the pharmaceutical sector has driven the stock's rise, with increased market attention. 4. Novonix: up 9.38%, the enthusiasm for new energy themes remains high, with continuous short-term capital inflows. 5. Sky Quarry: up 9.29%, the active performance of environmental concept stocks has driven the stock's rise. 6. Semilux: up 8.71%, the strong performance of the semiconductor sector has benefited this stock, with significant capital inflows. 7. Kosmos Energy: up 8.08%, the overall recovery of the energy sector has driven the stock's rise

Price Alert

KALA BIO

Innoviz Tech

Nine Energy

Cue BioPharma

Novonix

Sky Quarry

Wing Yip Food China

Semilux

Kosmos Energy

Zenas Biopharma

American Bitcoin

Novo Nordisk AS

Murano Global BV

Ondas

Sandisk

ROYAL BANK OF CANADA

TotalEnergies SE

NINE ENERGY SERVICE INC

U.S. Stock Market Movement Update: Kala Bio leads with a 20% increase, biotech stocks are active, Redhill Biopharma drops 9%

Market Overview of US Stocks in the Last Hour The US stock market has shown a significant sector rotation in the past hour, with the pharmaceutical and energy sectors performing particularly well. Small-cap stocks and thematic stocks have seen concentrated gains, with funds gradually shifting their preference towards these sectors. The overall market rhythm is fast-paced, with considerable volatility and a noticeable increase in short-term enthusiasm. The most notable stock in the last hour is Kala Pharmaceuticals, which surged by 23.10%. Driven by the pharmaceutical sector, short-term funds have flowed in, pushing the stock price up rapidly. Strong stocks: 1. Nine Energy: up 12.12%, driven by the strong performance of the energy sector, with active short-term funds. 2. Semilux: up 10.57%, performing excellently under the influence of the technology sector, with significant fund inflow. 3. Novonix: up 10.16%, benefiting from the sustained enthusiasm in the new energy sector. 4. Cue BioPharma: up 9.51%, boosted by the strong performance of the pharmaceutical sector. 5. Bakkt: up 9.47%, with increased enthusiasm for digital currency-related themes driving the stock up. 6. Sky Quarry: up 9.39%, with rising attention to environmental themes and significant fund inflow. 7. Kosmos Energy: up 8.08%, driven by the overall strength of the energy sector

Bakkt

Unilever

Lavoro

Alnylam Pharma

LAVORO LIMITED

U.S. Stock Movement Update: Kala BioPharma leads with a 23% increase, energy stocks are active, Wing Yip Food drops 9%

RedHill Biopharma shares are trading higher after the company announced development progress for RHB-102.

benzinga_article

Redhill Biopharma(RDHL.US)

RedHill Biopharma Reshapes Talicia Franchise and Strengthens Balance Sheet in 2025 Results

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | CPIX Stock News

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | CPIX Stock News

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight | CPIX Stock News

U.S. Stock Market Movement Update: Kala Bio leads with a 20% increase, biotech stocks are active, Redhill Biopharma drops 9%

U.S. Stock Movement Update: Kala BioPharma leads with a 23% increase, energy stocks are active, Wing Yip Food drops 9%

RedHill Biopharma shares are trading higher after the company announced development progress for RHB-102.